Condensed consolidated statements of cash flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating activities
Net loss	$ (20,637)	$ (61,341)
Adjustments to reconcile net cash used in operating activities:
Stock-based compensation	3,393	7,017
Acquired in-process research and development		47,716
Depreciation and amortization	578	180
Loss on disposal of property and equipment	180
Amortization of operating lease right-of-use assets	784	76
Write-off of right-of-use asset upon lease termination	113
Unrealized foreign exchange loss		20
Changes in operating assets and liabilities:
Other current assets and other non-current assets	(5,026)	(453)
Accounts payable and accrued liabilities	5,125	(3,828)
Operating lease right-of-use assets	(169)
Operating lease liabilities	313	(145)
Net cash used in operating activities	(15,346)	(10,758)
Investing activities
Acquisition of Former Neoleukin, net of cash acquired		191
Purchase of property and equipment	(1,566)	(97)
Net cash provided by (used in) investing activities	(1,566)	94
Financing activities
Proceeds from issuance of common stock and pre-funded warrants, net of commissions of $4.6 million	71,675
Payment of offering costs	(355)
Proceeds from exercise of stock options	4,576	40
Payment on finance lease obligations	(49)	(7)
Net cash provided by financing activities	75,847	33
Effect of exchange rate changes on cash, cash equivalents and restricted cash		9
Net change in cash, cash equivalents and restricted cash during the period	58,935	(10,622)
Cash, cash equivalents and restricted cash, beginning of period	143,093	76,928
Cash, cash equivalents and restricted cash, end of period	202,028	66,306
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment unpaid at period-end	271
Operating lease liabilities arising from obtaining ROU asset	$ 10,618	$ 515